WebMar 3, 2024 · Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of all lymphomas. ... Based on regulatory approvals, some options may be indicated only for third-line therapy and ... WebOct 12, 2024 · Rationale: The standard of care for almost 30 years in patients with DLBCL who relapsed or were refractory to first-line therapy is combination chemoimmunotherapy followed by consolidation with high-dose chemotherapy and ASCT for fit responding patients, based on the results of the PARMA group trial. 3 An optimal second-line salvage …
Treatment strategies for patients with diffuse large B-cell …
WebSep 14, 2015 · Third-line salvage chemotherapy can lead to response followed by transplantation and long-term survival in DLBCL patients. ... is the standard second-line … WebApr 23, 2024 · First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) ZYNLONTA addresses an unmet need across a broad population of third-line (3L)+ r/r patients, including patients with DLBCL not otherwise specified, DLBCL arising from … aletta mondré
Despite Potential Benefits, Barriers to CAR T-Cell Therapy for DLBCL …
WebApr 10, 2024 · Genetic classification helps to disclose molecular heterogeneity and therapeutic implications in diffuse large B-cell lymphoma (DLBCL). Using whole exome/genome sequencing, RNA-sequencing, and ... WebMar 22, 2024 · Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma, affecting approximately 22,000 patients per year. ... They may receive third-line or subsequent chemotherapy regimens ... WebFeb 26, 2024 · High-dose chemotherapy and transplant remains the second-line standard of care for the majority of patients with relapsed/refractory diffuse large B-cell lymphoma; however, CAR T-cell therapy and ... aletta manzo